News for Guardant Health, Inc. (GH)

On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including substantial purchases in Tempus AI Inc. (NASDAQ:TEM), NVIDIA Corp. (NASDAQ:NVDA), 3iQ Ether Stakin

Cathie Wood-led Ark Invest made significant trades on Tuesday, involving major companies like Tesla Inc. (NASDAQ:TSLA), Coinbase Global Inc.

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:MRNA) and AbbVie (NYSE:ABBV), according to its prospectu

On June 13, 2025, Meghan Joyce, a Director at Guardant Health Inc (GH), sold 3,337 shares of the company, as reported in a SEC Filing. Following this transactio

Summary Guardant Health Inc (GH), a leader in precision oncology, announced that its Shield blood test for colorectal cancer (CRC) screening has been awarded Fa

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been

On June 9, 2025, Amirali Talasaz, Co-CEO of Guardant Health Inc (GH), sold 119,284 shares of the company, according to a SEC Filing. Following this transaction,

Shares of Guardant Health Inc (GH) surged 4.04% in mid-day trading on Jun 9. The stock reached an intraday high of $50.00, up from its previous close of $48.0

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in [url="]ESMO Open[/url].T

Founded in 2008, Caris specializes in precision oncology and helps diagnose cancer through its tumor profiling and blood-based cancer diagnostics. The company, whose rivals include Roche's Foundation Medicine, Guardant Health, and Grail, generates a majority of its revenue from its tissue-based molecular profiling which helps select the appropriate cancer therapy. In 2021, Caris raised $830 million at a $7.83 billion valuation in a Sixth Street-led funding round.

Cathie Wood's Ark Invest made a blockbuster purchase of Circle Internet Group (NYSE:CRCL) shares on Thursday, marking a significant move in the evolving digital assets landscape.

On June 3, 2025, Kumud Kalia, Chief Information Officer at Guardant Health Inc (GH), sold 4,000 shares of the company. Following this transaction, the insider n

On Wednesday, Cathie Wood's Ark Invest sold 40,035 shares of Palantir Technologies Inc, amidst controversy. They bought shares of Guardant Health Inc and Veracyte Inc.

ARK Investment, led by Cathie Wood, made a significant move by purchasing 173,000 shares of Guardant Health (GH) today. This acquisition highlights ARK's contin

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of Signet Jewelers Limited SIG rose sharply during Tuesday's se...

Key Takeaways: Guardant Health's Shield test receives the FDA's breakthrough device designation. Analysts forecast a significant potential upside with price

Guardant Health, known by its stock ticker GH, has announced a significant milestone with the FDA granting Breakthrough Device designation for its innovative Sh

Cathie Wood's ARK Investment has expanded its portfolio by purchasing approximately 158,700 shares of Guardant Health (GH). This latest acquisition reflects the

Shares of Guardant Health Inc (GH) surged 3.50% in mid-day trading on Jun 2. The stock reached an intraday high of $42.11, before settling at $42.04, up fro